Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL7469544 | 0.96 | LMNA (0.37) | NOD1NOD2CMA1PSEN1PSEN2 | |
| Iodide SCHEMBL7467982 | 0.94 | PPARG (0.39) | NOD1NOD2PSEN1PSEN2APH1B | |
| Bromide SCHEMBL7469454 | 0.90 | PSEN1 (0.38) | NOD1NOD2CMA1PSEN1PSEN2 | |
| Iodide SCHEMBL7466546 | 0.90 | MAT2A (0.34) | HTTLMNAAPOBEC3AAPOBEC3GPTGDR2 | |
| Iodide SCHEMBL7462206 | 0.89 | CMA1 (0.38) | NOD1NOD2CMA1PSEN1PSEN2 | |
| Bromide SCHEMBL4450841 | 0.86 | PSEN1 (0.35) | NOD1NOD2CMA1PSEN1PSEN2 | |
| SCHEMBL8784743 | 0.86 | ALDH3A1 (0.43) | NOD1NOD2CMA1PSEN1PSEN2 | |
| SCHEMBL7472829 | 0.84 | CMA1 (0.45) | NOD1NOD2CMA1PSEN1PSEN2 | |
| Iodide SCHEMBL7464172 | 0.84 | GAA (0.35) | NOD1NOD2HPGDKDM4EALDH1A1 | |
| SCHEMBL7460693 | 0.84 | CMA1 (0.40) | NOD1NOD2CMA1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | INOUE JUN (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1224945-A1 | TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-0795548-B1 | QUINAZOLINE DERIVATIVES AND USE THEREOF | SUNTORY LTD (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1112749-A2 | PREVENTIVES OR REMEDIES FOR EYE CIRCULATORY FAILURE | Senju Pharmaceutical Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| US-5814631-A | CHYMASE INHIBITOR, CARDIVASCULAR | SUNTORY LIMITED (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0795548-A1 | QUINAZOLINE DERIVATIVES AND USE THEREOF | SUNTORY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | CMA1, THOP1, TPSAB1 | NOD1 4718/4885NOD2 4751/4885CMA1 1/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | NOD1 3107/4885NOD2 288/4885CMA1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.